Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.25
-6.7%		$2.53
$1.22
▼
$5.48
$125.43M354,075 shs106,832 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-4.29%-11.26%-58.64%-57.73%-64.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.25
-6.7%		$2.53
$1.22
▼
$5.48
$125.43M354,075 shs106,832 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-4.29%-11.26%-58.64%-57.73%-64.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
2.29
Hold$5.46336.80% Upside

Current Analyst Ratings Breakdown

Latest CLLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Underweight$9.00 ➝ $1.30
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$10.00 ➝ $8.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$4.00 ➝ $3.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
7/17/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$79.59M1.58N/AN/A$0.76 per share1.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$67.59M-$0.65N/AN/AN/A-102.34%-94.19%-21.34%11/13/2026 (Estimated)

Latest CLLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026H1 2026
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.2630-$0.22+$0.0430-$0.22$11.05 million$6.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
1.61
1.37
1.37

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
229100.34 million83.87 millionOptionable

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
October 8 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-sa--clls-302902143.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
October 6 at 4:33 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3376049/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-s-a-clls.html
Monthly information on share capital and company voting rights
October 6 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3376041/0/en/monthly-information-on-share-capital-and-company-voting-rights.html
Cellectis SA - depositary receipt price target decreased by 53.47% to $3.63
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cellectis-sa-depositary-receipt-price-target-decreased-by-53-47-to-3-63/ar-AA2dpQ8k
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-cellectis-unveils-in-vivo-gene-editing-plans-for-severe-lipid-disorders-2026-10-01/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-sa--clls-302895500.html
Cellectis S.A. (NASDAQ:CLLS) Short Interest Update
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-cellectis-sa-nasdaq-clls-short-interest-update-2026-09-30/
Cellectis S.A. (NASDAQ:CLLS) Stock Has Average Target Price of $5.46 According to Brokerages
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068742
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-cellectis-sa-nasdaq-clls-stock-has-consensus-price-target-of-546-2026-09-30/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371417/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-s-a-clls.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
September 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-sa--clls-302889627.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366962/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cellectis-s-a-clls.html
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
September 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260919446999/en/clls-investors-have-opportunity-to-join-cellectis-s.a.-fraud-investigation-with-sbs-law/
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud ...
September 17, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/09/17/10447842.htm
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3364336/0/en/clls-investor-alert-investigation-of-cellectis-s-a-announced-by-holzer-holzer-llc.html
Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
September 17, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/cellectis-clls-exits-two-car-t-programs-can-gene-editing-justify-the-clinical-reset-1837922/
Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)
September 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CLLS/pressreleases/4630356/analysts-offer-insights-on-healthcare-companies-cellectis-sa-clls-and-arrivent-biopharma-inc-avbp/
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
September 16, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/09/16/10447189.htm
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
September 16, 2026  |  financialcontent.comF
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
September 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260916371522/en/securities-fraud-investigation-into-cellectis-s.a.-clls-announced-%e2%80%93-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r.-cruz/
Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring
September 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947000-cellectis-an-all-or-nothing-pivot-to-in-vivo-gene-editing-is-worth-monitoring

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.25 -0.09 (-6.72%)
Closing price 04:00 PM Eastern
Extended Trading
$1.24 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas